glp-1 risks and side effects 💡 New research suggests a possible effect of medications. The study found: ✔️ 48% higher risk of smell or taste disorders ✔️ 81% higher risk of smell changes ✔️ 52% Struggling with GLP-1 therapy side

Interestingly, mice pre-treated with mGIPR-Ab/P3 followed by vehicle show increased c-Fos activation in the AP but a non-significant decrease in c-Fos + cells when followed by DA-GIP treatment (Extended Data Fig

Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)

When to Start GLP-1 After Gastric Bypass: Timing, Diet, and Success Strategies For patients exploring options to maximize their weight loss journey, knowing when to start GLP-1 after gastric bypass is a hot topic

Warren M, Chaykin L, Trachtenbarg D, Nayak G, Wijayasinghe N, Cariou B

GIP receptor antagonist, SKL-14959 indicated alteration of the lipids metabolism to catabolism by the inhibition of plasma LPL activity, resulting in the suppression of weight gain on diets-induced obesity mice